Jove
Visualize
联系我们
JoVE
x logofacebook logolinkedin logoyoutube logo
关于 JoVE
概览领导团队博客JoVE 帮助中心
作者
出版流程编辑委员会范围与政策同行评审常见问题投稿
图书馆员
用户评价订阅访问资源图书馆顾问委员会常见问题
研究
JoVE JournalMethods CollectionsJoVE Encyclopedia of Experiments存档
教育
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab Manual教师资源中心教师网站
使用条款与条件
隐私政策
政策

相关概念视频

Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein01:20

Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein

341
Antiepileptic drugs, such as levetiracetam (Keppra) and brivaracetam (Briviact), have emerged as crucial tools in managing epilepsy. These medications exert their therapeutic effects by targeting the synaptic vesicle protein SV2A, a transmembrane glycoprotein primarily found in the brain.
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
341
Antiepileptic Drugs: Potassium Channel Activators01:20

Antiepileptic Drugs: Potassium Channel Activators

210
Ezocgabine or retigabine, an antiepileptic drug of remarkable efficacy, has revolutionized the management of seizures. It is a potassium channel activator, explicitly targeting the family of Q subtype potassium channels. It enhances the transmembrane potassium currents, regulating neuronal excitability. This action stabilizes the resting membrane potential, a pivotal factor in mitigating the hyperexcitability that characterizes epilepsy.
Ezogabine has gained approval as an adjunctive treatment...
210
Antiepileptic Drugs: GABAergic Pathway Potentiators01:18

Antiepileptic Drugs: GABAergic Pathway Potentiators

453
γ-aminobutyric acid or GABA, plays a pivotal role as an inhibitory neurotransmitter in the brain. GABA pathway potentiators, also known as GABAergic drugs, are a class of pharmaceutical agents designed to enhance the functioning of the GABAergic system. These medications primarily treat epilepsy, a neurological disorder characterized by recurrent seizures.
The key GABA pathway potentiators used in epilepsy management are as follows.
Benzodiazepines are a well-known class of drugs used for...
453
Seizures: Classification01:13

Seizures: Classification

408
Epilepsy is primarily characterized by unpredictable seizures, either provoked by an identifiable factor, such as injury or illness, or unprovoked, occurring spontaneously without apparent cause.
Seizures are typically classified into two main categories: focal and generalized seizures.
Focal Seizures
Focal seizures originate from specific regions of the brain. These seizures are further sub-classified into two types:
408
Antiepileptic Drugs: Glutamate Antagonists01:14

Antiepileptic Drugs: Glutamate Antagonists

418
Glutamate is a fundamental neurotransmitter in the central nervous system, playing a vital role in neuronal communication and various cognitive processes. Glutamate stands as the principal excitatory neurotransmitter in the brain. Its presence is crucial for the communication between neurons, underpinning essential processes such as synaptic transmission, neuronal excitability, and plasticity. These functions are vital for higher-order cognitive processes, including learning and memory. The...
418
Alzheimer's Disease: Treatment01:22

Alzheimer's Disease: Treatment

212
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
212

您也可能阅读

相关文章

通过共同作者、期刊和引用图与本文相关的文章。

排序
Same author

Cortical stimulation reveals effective disconnection of the epileptogenic network at seizure onset.

Epilepsia·2026
Same author

Efficacy and Safety of Patients With Relapsing Multiple Sclerosis Switching to Ocrelizumab Due to Suboptimal Treatment Response: Results of the 4-Year CASTING-LIBERTO Trial.

European journal of neurology·2026
Same author

Increased functional network connectivity following cognitive rehabilitation in progressive multiple sclerosis with moderate to severe disabilty: findings from the CogEx study.

Journal of neurology·2026
Same author

Caution in interpreting disease-modification claims with lecanemab: Selective reporting and causal inference.

Alzheimer's & dementia : the journal of the Alzheimer's Association·2026
Same author

Increased interval between seizure clusters across time in pediatric patients treated with the immediate-use seizure medication diazepam nasal spray.

Epilepsia·2026
Same author

Closing the Gap to Interventions for Tuberous Sclerosis Complex-Associated Neuropsychiatric Disorders (TAND): Protocol for a Longitudinal Study of TAND Severity, Predictors, and Caregiver Well-Being (TANDem-2).

JMIR research protocols·2026

相关实验视频

Updated: Jul 17, 2025

Electrophoretic Delivery of γ-aminobutyric Acid GABA into Epileptic Focus Prevents Seizures in Mice
07:01

Electrophoretic Delivery of γ-aminobutyric Acid GABA into Epileptic Focus Prevents Seizures in Mice

Published on: May 16, 2019

9.1K

早期使用维加巴特林治疗不能减少焦点发作或改善结核性硬化综合体的认知:PREVeNT试验

Elizabeth Martina Bebin1, Jurriaan M Peters2, Brenda E Porter3

  • 1Department of Neurology, University of Alabama at Birmingham, Birmingham, AL, USA.

Annals of neurology
|August 28, 2023
PubMed
概括
此摘要是机器生成的。

在结核性硬化综合体 (TSC) 婴儿的早期vigabatrin治疗没有改善神经认知结果. 然而,它与较晚的发病和较低的婴儿发病率有关,这表明对特定发作类型的潜在益处.

更多相关视频

Author Spotlight: Obtaining High-Quality CSF and Blood Samples for Epilepsy Biomarker Discovery
10:46

Author Spotlight: Obtaining High-Quality CSF and Blood Samples for Epilepsy Biomarker Discovery

Published on: September 1, 2023

3.1K
MRI-guided Focused Ultrasound Thalamotomy for Patients with Medically-refractory Essential Tremor
05:54

MRI-guided Focused Ultrasound Thalamotomy for Patients with Medically-refractory Essential Tremor

Published on: December 13, 2017

14.0K

相关实验视频

Last Updated: Jul 17, 2025

Electrophoretic Delivery of γ-aminobutyric Acid GABA into Epileptic Focus Prevents Seizures in Mice
07:01

Electrophoretic Delivery of γ-aminobutyric Acid GABA into Epileptic Focus Prevents Seizures in Mice

Published on: May 16, 2019

9.1K
Author Spotlight: Obtaining High-Quality CSF and Blood Samples for Epilepsy Biomarker Discovery
10:46

Author Spotlight: Obtaining High-Quality CSF and Blood Samples for Epilepsy Biomarker Discovery

Published on: September 1, 2023

3.1K
MRI-guided Focused Ultrasound Thalamotomy for Patients with Medically-refractory Essential Tremor
05:54

MRI-guided Focused Ultrasound Thalamotomy for Patients with Medically-refractory Essential Tremor

Published on: December 13, 2017

14.0K

科学领域:

  • 儿科神经学 儿科神经学
  • 发病学 (Epileptology) 是一个专业的学科.
  • 发育神经科学的发展神经科学.

背景情况:

  • 结核性硬化综合体 (TSC) 是一种与和发育挑战相关的遗传疾病.
  • 早期干预对于优化TSC婴儿神经发育结果至关重要.
  • 维加巴特林是治疗婴儿的既定治疗方法,但其在预防其他类型的和改善TSC整体神经认知方面的作用仍在调查中.

研究的目的:

  • 评估早期vigabatrin治疗的疗效,在形脑电图 (EEG) 活动开始时开始,与患有TSC的婴儿在发作时的治疗相比.
  • 为了确定早期vigabatrin对24个月龄神经认知结果的影响.
  • 评估早期vigabatrin对发病率,耐药性和安全性的影响.

主要方法:

  • 一个IIb期,多中心,随机,双盲,安慰剂受控试验.
  • 患有TSC的婴儿在第一次形脑电图 (EEG) 或在发作开始时接受了vigabatrin.
  • 主要结局:贝利婴儿和幼儿发展尺度,第三版 (贝利-III). 24个月的认知评分.

主要成果:

  • 在24个月后,早期vigabatrin和安慰剂组之间没有观察到贝利-III认知评分的显著差异.
  • 与安慰剂相比,早期vigabatrin没有显著改变整体发病率或耐药性的发病率.
  • 维加巴林组的发病率较低,婴儿的发病时间较晚,各组的不良事件概况相似.

结论:

  • 在发作发作之前基于EEG型活动的vigabatrin的启动不会改善TSC婴儿24个月的神经认知结果.
  • 预防性vigabatrin不会延迟发作或减少该人群中焦点发作和耐药性的发生率.
  • 早期vigabatrin治疗在减少TSC婴儿婴儿发作的发生率和延迟发作方面具有好处.